Results 71 to 80 of about 4,942 (259)

Reduction of High Cholesterol Levels by a Preferably Fixed-Combination Strategy as the First Step in the Treatment of Hypertensive Patients with Hypercholesterolemia and High/Very High Cardiovascular Risk: A Consensus Document by the Italian Society of Hypertension [PDF]

, 2022
The primary and secondary prevention strategies of atherosclerotic cardiovascular disease (ASCVD) largely rely on the management of arterial hypertension and hypercholesterolemia, two major risk factors possibly linked in pathophysiological terms by the ...
Agabiti Rosei C., Agnoletti D., Borghi C., Cicero A. F. G., De Ciuceis C., Del Pinto R., Desideri G., Ferri C., Grassi D., Grassi G., Muiesan M. L., Paini A., Salvetti M., Tocci G., Veglio F., Volpe M.   +15 more
core   +1 more source

Progress in RNA‐Targeted Therapeutics for Human Diseases

MedComm, Volume 7, Issue 2, February 2026.
RNA‐targeted therapies are revolutionizing molecular medicine by transitioning from a “protein‐centric” focus to an “RNA‐regulatory network” approach. Leveraging RNA's diverse roles in gene regulation, signaling, and epigenetic modifications, advanced platforms such as ASOs, siRNA, miRNA, mRNA, aptamers, shRNA, and CRISPR/Cas systems are enabling ...
Wangzheqi Zhang, Aimin Jiang, Bin‐Kui Jia, Yuming Jin, Yinghu Chen, Zhaoyu Li, Yan Liao, Haoling Zhang, Zhiheng Lin, Xiao Fang, Linhui Wang   +10 more
wiley   +1 more source

Appropriateness of Dyslipidemia Management Strategies in Post-Acute Coronary Syndrome: A 2023 Update

Metabolites, 2023
It has been consistently demonstrated that circulating lipids and particularly low-density lipoprotein cholesterol (LDL-C) play a significant role in the development of coronary artery disease (CAD).
Fabiana Lucà, Fabrizio Oliva, Carmelo Massimiliano Rao, Maurizio Giuseppe Abrignani, Antonio Francesco Amico, Stefania Angela Di Fusco, Giorgio Caretta, Irene Di Matteo, Concetta Di Nora, Anna Pilleri, Roberto Ceravolo, Roberta Rossini, Carmine Riccio, Massimo Grimaldi, Furio Colivicchi, Michele Massimo Gulizia   +15 more
doaj   +1 more source

RNA-Peptide nanoplexes drug DNA damage pathways in high-grade serous ovarian tumors [PDF]

, 2018
DNA damaging chemotherapy is a cornerstone of current front‐line treatments for advanced ovarian cancer (OC). Despite the fact that a majority of these patients initially respond to therapy, most will relapse with chemo‐resistant disease; therefore ...
Barberio, Antonio Eric, Correa Echavarria, Santiago, Dreaden, Erik, Elias, Kevin, Gallagher, Paige N., Hammond, Paula T, Hwang, Mun Kyung, Kong, Yi Wen, Oberlton, Benjamin J., Quadir, Mohiuddin Abdul, Shi, Aria C., Shopsowitz, Kevin, Suarez Lopez, Lucia, Yaffe, Michael B   +13 more
core   +1 more source

Management of Familial Hypercholesterolemia: Current Status and Future Perspectives [PDF]

, 2021
Familial hypercholesterolemia (FH) is the most common monogenic disorder associated with premature atherosclerotic cardiovascular disease. Early diagnosis and effective treatment can significantly improve prognosis.
Lee, ACH, Lui, DTW, Tan, KCB
core   +1 more source

Rationale and Design of the PASSIVATE‐CAP Trial: The Preventive Intervention Value of Drug‐Coated Balloons in Vulnerable Coronary Atherosclerotic Plaques

Clinical Cardiology, Volume 49, Issue 1, January 2026.
PASSIVATE‐CAP Research Overview and Flowchart. ABSTRACT Background Patients with acute coronary syndrome (ACS) face a significantly increased risk of cardiovascular events due to vulnerable plaques. However, no clear evidence supports performing preventive percutaneous coronary intervention (PCI) for non‐flow‐limiting vulnerable plaques.
Zhongxiu Chen, Junyan Zhang, Minggang Zhou, Shichu Liang, Yong Chen, Chen Li, Hua Wang, Jiafu Wei, Baotao Huang, Mian Wang, Yong He, for the PASSIVATE‐CAP trial investigator   +11 more
wiley   +1 more source

Evaluating the implementation of inclisiran in primary care: process evaluation interim findings from interviews with key stakeholders

BMJ Open
Objectives VICTORION-Spirit was a hybrid study designed to assess the feasibility of implementing inclisiran, a novel cholesterol-lowering treatment and behavioural support within primary care centres in England. This process evaluation aimed to evaluate
Peter Bower, Samantha Dixon, Paul Wilson, Amy Mathieson, Rebecca Elvey, Martin Gibson, Tracey Vell   +6 more
doaj   +1 more source

Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular Diseases

Biomedicines, 2021
Lipoprotein(a) (Lp(a)) is a low density lipoprotein particle that is associated with poor cardiovascular prognosis due to pro-atherogenic, pro-thrombotic, pro-inflammatory and pro-oxidative properties.
Victoria A. Korneva, Tatjana Yurjevna Kuznetsova, Ulrich Julius   +2 more
doaj   +1 more source

Optimization of 4‐Amino‐2‐Pyridone Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9: Integrating Structure–Activity and Structure–Metabolism Relationships

ChemMedChem, Volume 21, Issue 1, January 2026.
Green chemistry‐based late‐stage functionalization (LSF) of the anti‐proprotein convertase subtilisin/kexin type 9 (PCSK9) early lead compound 5c led to optimized analogs with improved metabolic stability/PCSK9 IC50 ratio. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key drug target for the treatment of different hypercholesterolemia ...
Lisa Giannessi, Maria Giovanna Lupo, Martina Ugolotti, Bianca Papotti, Beatrice Mattina, Maria Grazia Martina, Anna Demurtas, Cristina Padula, Sara Nicoli, Marco Crescenzio, Nicola Ferri, Francesca Zimetti, Marco Radi   +12 more
wiley   +1 more source

2021 FDA TIDES (Peptides and Oligonucleotides) Harvest

Pharmaceuticals, 2022
From the medical, pharmaceutical, and social perspectives, 2021 has been a year dominated by the COVID-19 pandemic. However, despite this global health crisis, the pharmaceutical industry has continued its endeavors, and 2021 could be considered an ...
Danah Al Shaer, Othman Al Musaimi, Fernando Albericio, Beatriz G. de la Torre   +3 more
doaj   +1 more source